KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Equity Income (2020 - 2023)

BeOne Medicines (ONC) has disclosed Equity Income for 4 consecutive years, with -$3.9 million as the latest value for Q4 2023.

  • On a quarterly basis, Equity Income rose 29.29% to -$3.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$16.2 million, a 26.25% increase, with the full-year FY2023 number at -$16.2 million, up 26.25% from a year prior.
  • Equity Income was -$3.9 million for Q4 2023 at BeOne Medicines, up from -$10.1 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $23.2 million in Q3 2021 to a low of -$17.0 million in Q1 2022.
  • A 4-year average of -$1.2 million and a median of -$2.4 million in 2021 define the central range for Equity Income.
  • Biggest YoY gain for Equity Income was 1898.37% in 2021; the steepest drop was 614.79% in 2021.
  • BeOne Medicines' Equity Income stood at $1.9 million in 2020, then tumbled by 614.79% to -$9.5 million in 2021, then skyrocketed by 41.44% to -$5.6 million in 2022, then increased by 29.29% to -$3.9 million in 2023.
  • Per Business Quant, the three most recent readings for ONC's Equity Income are -$3.9 million (Q4 2023), -$10.1 million (Q3 2023), and -$2.0 million (Q2 2023).